MannKind (MNKD) Stock Analysis & AI Equity Report
MannKind (MNKD) overview
MannKind (MNKD) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 349m and operating profit of USD 38.8m; the year-end share price was 5.67 USD and market capitalisation was USD 1,745m. MannKind is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get MannKind's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About MannKind
MannKind is a biopharmaceutical company developing and commercializing treatments for cardiometabolic and orphan lung diseases. Its commercial products include Afrezza inhaled insulin and the V-Go wearable insulin delivery device for diabetes, and Furoscix furosemide injection for edema associated with heart failure or chronic kidney disease. The company also develops inhaled therapies with United Therapeutics, which commercializes Tyvaso DPI for pulmonary hypertension.
Generate the MannKind report
MannKind is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for MannKind and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on MannKind
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.